Teresa  Diaz-Montes, M.D., MPH, FACOG

Teresa Diaz-Montes, M.D., MPH, FACOG

Mercy Medical Center

Associate Director, The Lya Segall Ovarian Cancer

Expertise: Gynecologic OncologyGynecologyGynecologic SurgeryGynecologic CancerFertility

Teresa P. Diaz-Montes, M.D., MPH, FACOG, serves as the Associate Director of The Lya Segall Ovarian Cancer Institute. She also is a noted expert and gynecologic oncologist with The Gynecologic Oncology Center at Mercy, a leading Center in Baltimore for the treatment of cancers of the female reproductive tract. Dr. Teresa Diaz-Montes provides diagnosis and treatment for gynecologic cancers including ovarian cancer, cervical cancer, uterine cancer, vaginal cancer, and vulvar cancer. Board Certified in Gynecologic Oncology, Dr. Teresa Diaz-Montes provides treatment for a diverse range of gynecologic cancers. Her primary clinical interests include ovarian cancer treatments, minimally invasive gynecologic surgery, including robotic surgery, and patient safety and quality. Additional areas of interest include cervical cancer, fallopian tube cancer, fertility-sparing surgery and uterine, vaginal and vulvar cancers. Bringing a friendly approach to the treatment of her patients, Dr. Diaz-Montes takes the necessary time to listen to the needs of her patients and address their concerns. As a recipient of the Patient's Choice award, her approachable, caring bedside manner has been formally recognized by her patients. Dr. Teresa Diaz-Montes is known for her knowledge and dedication to finding advanced treatments for gynecologic cancers. Her expert opinion is often sought by media outlets and she has been featured in notable publications such as The Wall Street Journal and The New York Times. She was also featured by The Sun Magazine as "One of 50 Women to Watch" for her dedication to innovative treatments for ovarian cancer. Dr. Diaz-Montes has extensive experience in research and resident teaching activities. She has conducted various clinical trials to advance the care of gynecologic cancers, particularly ovarian cancer. She and colleagues in The Institute for Cancer Care at Mercy are conducting the first clinical study in the United States regarding the treatment of ovarian cancer with hyperthermic intraperitoneal chemotherapy, also known as HIPEC. Dr. Diaz-Montes, an author and international lecturer, has numerous clinical publications related to women’s cancer treatment to her credit.
Awards and Honors
Top Doctor in Gynecologic Oncology, Baltimore magazine
Top Doctor in Gynecologic Oncology, Castle Connolly Medical Ltd.

The new treatment turns up heat on ovarian cancer

"We are trying to see if we can be more proactive in preventing more women from recurring (with ovarian cancer),"

No Research/Citations

Latest developments on Cytoreductive Surgery & Hyperthermic Intraperitoneal Chemotherapy (CRT/HIPEC)

Mercy Medical Center is the first institution in the United States to study the role of CRS/HIPEC for newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancers. Literature exists involving CRS/HIPEC in the role of recurrent disease and in the neoadjuvant setting; however, there is no published data on the role as a primary treatment option in the United States.
17-Jul-2020 07:15:57 AM EDT

"Not all ovarian cysts cause symptoms. It is very normal for a woman to have cysts that develop and resolve without any intervention. Symptoms could be related to the location and size of the cyst."

- https://mdmercy.com/news-and-events/media-relations/news-by-mercy/2016/march/what-are-ovarian-cysts-and-how-can-they-be-treated

Media mobile No : 410-375-7342

Media office Phone : 410-332-9714

Media email : dcollins@mdmercy.com

close
0.13151